Illumina (ILMN) Earnings Expected to Grow: Should You Buy?

Core Viewpoint - Illumina is expected to report a year-over-year increase in earnings despite a decline in revenues, with the consensus outlook indicating a significant earnings surprise potential [1][3][11]. Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.91 per share, reflecting a year-over-year increase of +550%, while revenues are projected to be $1.08 billion, down 4.1% from the previous year [3][17]. - The earnings report is scheduled for release on February 6, 2025, and could influence stock movement based on whether the results exceed or fall short of expectations [2][12]. Estimate Revisions - The consensus EPS estimate has been revised 0.84% higher in the last 30 days, indicating a positive reassessment by analysts [4][10]. - Illumina's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +1.11%, suggesting a strong likelihood of beating the consensus EPS estimate [10][11]. Earnings Surprise History - Illumina has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters, including a +31.03% surprise in the most recent quarter [12][13]. - The company's past performance in matching or exceeding estimates may influence future earnings expectations [12]. Industry Comparison - GSK, another player in the biomedical and genetics industry, is expected to report earnings of $0.53 per share, indicating a year-over-year decline of -26.4%, with revenues projected at $10 billion, unchanged from the previous year [17][18]. - GSK's Earnings ESP is -9.86%, combined with a Zacks Rank of 4 (Sell), making it challenging to predict an earnings beat [18].